MED — Medifast Cashflow Statement
0.000.00%
Last trade - 00:00- $353.45m
- $203.41m
- $1.07bn
Annual cashflow statement for Medifast, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 77.9 | 103 | 164 | 144 | 99.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.63 | 7.88 | 15.1 | 19.3 | 13.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -8.51 | 26.6 | -87.6 | 21.7 | 20.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 84.3 | 145 | 94.5 | 195 | 148 |
| Capital Expenditures | -10.1 | -5.89 | -34.2 | -16.7 | -6.48 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.73 | 4.61 | 5.14 | 5.27 | -54.6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -6.33 | -1.28 | -29.1 | -11.4 | -61 |
| Financing Cash Flow Items | -14.1 | -0.551 | -6.09 | -1.52 | -3.36 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -82.3 | -57.1 | -125 | -200 | -79.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.39 | 86.7 | -59.5 | -16.5 | 6.75 |